Navigation Links
Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

ination with Capecitabine in Patients with Advanced Breast Cancer.
  • Patricia Gomez, M.D., Breast Cancer Center, Vall d'Hebron University Hospital, Barcelona, Spain
  • Abstract 1083, General Poster Session, Breast Cancer Track
  • Saturday, June 5, 2010, 2:00-6:00 p.m., S Hall A2

"With more than 70 investigator and company sponsored studies being presented at ASCO, we look forward to continuing our work with investigators to understand how Nexavar may fit into other areas of the therapeutic landscape, particularly with respect to how biomarkers status may guide selection of therapy, which is a step toward personalized medicine," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development at Onyx Pharmaceuticals.  

Nexavar's Differentiated Mechanism

Nexavar, an oral anti-cancer therapy, is currently approved in more than 90 countries for liver cancer where it remains the only approved systemic agent proven to extend survival and in more than 95 countries for the treatment of patients with advanced kidney cancer.  Nexavar inhibits processes involved in both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth.  These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFRB, KIT, FLT-3 and RET.  

Nexavar is also being evaluated by other companies, international study groups, government agencies a
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
2. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
3. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
4. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
5. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
9. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
10. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
11. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Research and Markets ( ... PharmaBiotech,s new report "Personalized Medicine - Scientific ... , The aim of personalized medicine ... drug to the right patient and, in some ... a patient according to his/her genotype. This report ...
(Date:3/3/2015)... , March 3, 2015 ... with tools for implementing competency-based training to comply with ... DirectCourse is offering a new crosswalk tool ... (HCBS) implement competency-based training for direct service workers as ... & Medicaid Services (CMS) regulations. CMS amended ...
(Date:3/3/2015)... , March 3, 2015  PDL BioPharma, Inc. (PDL ... announced that the third of three shareholder lawsuits filed ... prejudice. On February 2, 2015, a securities ... on behalf of a putative class of purchasers of ... al., No. 2:14-CV-01526-APG-NJK (D. Nev.), was voluntarily dismissed without ...
(Date:3/2/2015)... March 02, 2015 Shimadzu Scientific Instruments ... present on LCMS and marijuana analysis at the Pittcon ... 8 to 12 at the Ernest N. Morial Convention ... stop by booth 3121 to discuss laboratory challenges with ... innovative, proven products help save time, money and effort ...
Breaking Biology Technology:Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 2Elsevier's DirectCourse Can Help States Meet and Exceed New CMS Requirements for Home and Community-Based Services 3PDL BioPharma Announces Dismissal of Third and Final Shareholder Lawsuit 2Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 2Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 3
... 2011 TriLink BioTechnologies, Inc. (TriLink) announced that it ... (TATAA) to sell its CleanAmp™ Products. The Scandinavian based ... qPCR courses worldwide, in addition to providing tailor-made products ... innovative approach to Hot Start PCR, TriLink,s CleanAmp™ Product ...
... March 25, 2011 BioNeutral Group, Inc. (OTC Bulletin ... technology-based company, today announced the appointment of Dr. Stephen ... and a medical practitioner in New York State, as ... Director. Dr. Holt is an independent consultant to the ...
... Diagnostic Laboratory, Inc. (HDL, Inc.) and BG Medicine, Inc. (Nasdaq: ... HDL, Inc. will offer galectin-3 testing services based on the ... Galectin-3 Test was recently cleared by the FDA as an ... failure. Elevated galectin-3 levels are associated with an inherently progressive ...
Cached Biology Technology:TriLink Enters Into Distribution Agreement With TATAA Biocenter 2BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board 2BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board 3Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 2Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 3Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 4
(Date:2/5/2015)... 28, 2015 Research and Markets ... the "Global Biometrics Market (2014-2020): Market Forecast ... report to their offering. , ... is anticipated to overtake ... increasing government spending towards IT security, government biometric ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
(Date:1/22/2015)... OXFORD, Conn. , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: ... growing mobile commerce market, reports on the recent success of the Wocket™ ... Wocket smart wallet was named as one of the ... of the "5 Best Products Launched At CES So Far" by Newseveryday.com ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... Boston, MA (Jan. 18, 2012) The National ... Research Institute, a subsidiary of Mass. Eye and Ear, ... understand the origins of eye allergies (NEI Grant Number ... principal investigator for the project formally entitled "Cellular and ...
... new approach to motion capture technology is offering fresh ... general. Researchers studied three types of tennis serves, ... which creates the highest potential for shoulder injury. ... Annals of Biomedical Engineering , could aid sports training ...
... of microbiologists led by Indiana University researchers has identified a ... single end or pole of the cell instead of uniform, ... that could have implications in the development of new antibacterial ... bacteria such as Escherichia coli and Bacillus ...
Cached Biology News:Markerless motion capture offers a new angle on tennis injuries 2Markerless motion capture offers a new angle on tennis injuries 3Markerless motion capture offers a new angle on tennis injuries 4Polar growth at the bacterial scale reveals potential new targets for antibiotic therapy 2Polar growth at the bacterial scale reveals potential new targets for antibiotic therapy 3
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Use the DUALmembrane kit 3 to carry out DUALmembrane interaction analysis and cDNA library screening to characterize interactions between integral membrane proteins and to identify novel interaction ...
... effectively seals labware. Waterproof, moisture-proof film ... materials. Can be folded repeatedly and ... Stretched lengthwise at 21C (70F), wrapping ... tension is removed, film only partially ...
Biology Products: